Molecular understanding of combination epigenetic therapy in MLL-fusion leukaemia

MLL 融合白血病联合表观遗传疗法的分子理解

• 批准号: nhmrc : 1066545
• 负责人: Prof Mark Dawson
• 金额: $ 41.65万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/molecular-understanding-combination-fusion-leukaemia/455244
• 关键词: Molecular; understanding; combination; epigenetic; therapy

The poor prognosis conferred by chromosome breaks involving the MLL gene in acute leukaemia has not significantly changed in over twenty years. This fact highlights the urgent need to identify and develop novel therapeutic agents for this disease. This project will aim to understand the mechanisms leading to the initiation and maintenance of this aggressive disease. We will then use these insights to develop a rational combination of therapeutic agents.

急性白血病中涉及MLL基因的染色体断裂所导致的不良预后在二十多年来没有显著改变。这一事实突出了迫切需要确定和开发新的治疗药物，这种疾病。该项目旨在了解导致这种侵袭性疾病的启动和维持的机制。然后，我们将使用这些见解来开发合理的治疗药物组合。